38 research outputs found
Patient’s age as a factor in the use of diagnostic tools and evidence based therapies in patients with heart failure
Multiple alcohol septal ablations in a young patient with hypertrophic cardiomyopathy
A 16 year old female with hypertrophic cardiomyopathy was treated with alcohol ablation for
NYHA class III symptoms on medical therapy. Three months later, patient underwent
a second alcohol ablation procedure for continued symptoms. Follow-up, for 4 years now,
continues to show resolution of symptoms. (Cardiol J 2007; 14: 301-304
Wielokrotna ablacja alkoholowa przegrody międzykomorowej u młodej pacjentki z kardiomiopatią przerostową
U 16-letniej pacjentki z kardiomiopatiÄ… przerostowÄ…, dotychczas leczonej za pomocÄ… farmakoterapii
(nasilenie objawów wstępnie oceniono jako III stopień wg skali NYHA), przeprowadzono
zabieg ablacji alkoholowej przegrody międzykomorowej mięśnia sercowego. Trzy miesiące
później z powodu utrzymujących się dolegliwości klinicznych chorą poddano drugiej z kolei
ablacji alkoholowej przegrody międzykomorowej mięśnia sercowego. W 4-letniej obserwacji
odnotowano ustÄ…pienie objawów klinicznych. (Folia Cardiologica Excerpta 2007; 2: 448–451
Design and Rationale of the Cognitive Intervention to Improve Memory in Heart Failure Patients Study
BACKGROUND:
Memory loss is an independent predictor of mortality among heart failure patients. Twenty-three percent to 50% of heart failure patients have comorbid memory loss, but few interventions are available to treat the memory loss. The aims of this 3-arm randomized controlled trial were to (1) evaluate efficacy of computerized cognitive training intervention using BrainHQ to improve primary outcomes of memory and serum brain-derived neurotrophic factor levels and secondary outcomes of working memory, instrumental activities of daily living, and health-related quality of life among heart failure patients; (2) evaluate incremental cost-effectiveness of BrainHQ; and (3) examine depressive symptoms and genomic moderators of BrainHQ effect.
METHODS:
A sample of 264 heart failure patients within 4 equal-sized blocks (normal/low baseline cognitive function and gender) will be randomly assigned to (1) BrainHQ, (2) active control computer-based crossword puzzles, and (3) usual care control groups. BrainHQ is an 8-week, 40-hour program individualized to each patient's performance. Data collection will be completed at baseline and at 10 weeks and 4 and 8 months. Descriptive statistics, mixed model analyses, and cost-utility analysis using intent-to-treat approach will be computed.
CONCLUSIONS:
This research will provide new knowledge about the efficacy of BrainHQ to improve memory and increase serum brain-derived neurotrophic factor levels in heart failure. If efficacious, the intervention will provide a new therapeutic approach that is easy to disseminate to treat a serious comorbid condition of heart failure
Development of a Protocol for Successful Palliative Care Consultation in Population of Patients Receiving Mechanical Circulatory Support
Background
In 2014, Joint Commission recommended palliative care (PC) engagement in ventricular assist device (VAD) implantation as destination therapy. Limited information is available on established PC protocols in the mechanical circulatory support (MCS) population.
Measures
The goals of our PC consultation were to document advance care planning (ACP) discussions and designate a surrogate decision maker (SDM) prior to MCS implantation. A retrospective analysis compared the frequency of PC consults, ACP discussion, and SDM before and after protocol implementation.
Intervention
A protocol was developed to conduct interdisciplinary PC consultations for the MCS population.
Outcomes
The percentage of PC consults placed prior to MCS implantation increased from 11 (17.2%) pre-protocol to 56 (96.6%) post-protocol (p<0.0001), and documented SDM increased from 26 (40.6%) pre-protocol to 57 (98.3%) post protocol (p<0.0001).
Conclusion
Close PC/cardiology collaboration can substantially improve ACP discussions and SDM documentation in the MCS population. This multidisciplinary protocol facilitates successful PC consultations
Evaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: a pilot study
D-Ribose, a pentose sugar, has shown to improve myocardial high-energy phosphate stores depleted by ischemia. This study investigated the ability of D-Ribose with low dose dobutamine to improve the contractile response of viable myocardium to dobutamine and to assess the efficacy of D-ribose in reducing stress-induced ischemia. Twenty-six patients with ischemic cardiomyopathy completed a two-day, randomized, double blind crossover trial comparing the effects of D-Ribose and placebo on regional wall motion. On the first study day, either D-Ribose or placebo was infused for 4.5 hours. Low (5 and 10 μ/kg/min) and subsequently, high (up to 50 μ/kg/min) dose dobutamine echocardiography was then performed. On the second study day, patients crossed over to the alternative article for a similar 4.5 hours infusion time period and underwent a similar evaluation. The wall motion response during low dose dobutamine was the same with D-Ribose and placebo in 77% of segments (203/263, Kappa = 0.37). In segments with discordant responses, more segments improved with D-Ribose than with placebo (41 vs. 19 segments, p = 0.006). With high dose dobutamine infusion, the wall motion response (ischemia vs. no ischemia) was the same with D-Ribose and placebo in 83% of interpretable segments (301/363, kappa = 0.244). In segments with discordant responses, there were more ischemic segments with placebo compared to D-Ribose (36 vs. 26, p = 0.253). Nineteen patients developed ischemia during the dobutamine and placebo infusion and 13 patients had ischemia during dobutamine and D-ribose infusion (p = 0.109). D-Ribose improved contractile responses to dobutamine in viable myocardium with resting dysfunction but had no significant effect in reducing the frequency of stress-induced wall motion abnormalities
Database queries for hospitalizations for acute congestive heart failure: flexible methods and validation based on set theory
Background and objective
Electronic health records databases are increasingly used for identifying cohort populations, covariates, or outcomes, but discerning such clinical ‘phenotypes’ accurately is an ongoing challenge. We developed a flexible method using overlapping (Venn diagram) queries. Here we describe this approach to find patients hospitalized with acute congestive heart failure (CHF), a sampling strategy for one-by-one ‘gold standard’ chart review, and calculation of positive predictive value (PPV) and sensitivities, with SEs, across different definitions.
Materials and methods
We used retrospective queries of hospitalizations (2002–2011) in the Indiana Network for Patient Care with any CHF ICD-9 diagnoses, a primary diagnosis, an echocardiogram performed, a B-natriuretic peptide (BNP) drawn, or BNP >500 pg/mL. We used a hybrid between proportional sampling by Venn zone and over-sampling non-overlapping zones. The acute CHF (presence/absence) outcome was based on expert chart review using a priori criteria.
Results
Among 79 091 hospitalizations, we reviewed 908. A query for any ICD-9 code for CHF had PPV 42.8% (SE 1.5%) for acute CHF and sensitivity 94.3% (1.3%). Primary diagnosis of 428 and BNP >500 pg/mL had PPV 90.4% (SE 2.4%) and sensitivity 28.8% (1.1%). PPV was <10% when there was no echocardiogram, no BNP, and no primary diagnosis. ‘False positive’ hospitalizations were for other heart disease, lung disease, or other reasons.
Conclusions
This novel method successfully allowed flexible application and validation of queries for patients hospitalized with acute CHF